Abstract: The present disclosure relates generally to fluorinated glucosamine analogs and uses thereof, including analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, such as multiple sclerosis; inflammation; cancer; central nervous system injury; or conditions associated with up-regulation of an extracellular matrix, such as chondroitin sulfate proteoglycans.

Abstract: The present disclosure relates to analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, inflammation, cancer and a central nervous system injury.

Abstract: In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as “MS”).

Abstract: The present disclosure relates to analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, inflammation, cancer and a central nervous system injury.

Abstract: In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as “MS”).

Abstract: A dosing regime for providing therapy for a neurological trauma such as spinal cord injury in a human subject. The dosing regime comprises intravenous administration of a plurality of minocycline doses for a 7-day period at 12-h intervals such that a steady state level of minocycline is reached and maintained in a subject's serum and/or cerebrospinal fluid after administration of three minocycline doses. An initial minocycline dose of at least 800 mg is preferably administered within 12 h after an occurrence of the neurological trauma. The minocycline dosage is sequentially tapered to 400 mg and then maintained at 400 mg for the remainder of the 7-day treatment period.